Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.250
Sell
RSI(14)
46.229
Neutral
STOCH(KDJ)(9,3,3)
33.983
Neutral
ATR(14)
1.067
High Vlolatility
CCI(14)
-29.919
Neutral
Williams %R
64.431
Sell
TRIX(12,20)
-0.207
Sell
StochRSI(14)
78.716
Buy
Search
Kazia Therapeutics Ltd
KZIAAdd to Watchlist
12.620USD
-0.200-1.56%
Close 07-31 16:00（ET）Quotes delayed by 15 min
102.15MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey ChartIntraday
1m
30m
1h
D
W
M
D
Today
-1.56%
5 Days
+2.94%
1 Month
-5.75%
6 Months
+115.36%
Year to Date
+83.16%
1 Year
+54.28%
Key Figures
13.130Open
13.550High
298.69KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
3.69%Turnover Ratio
12.820Prev. Close
12.520Low
2.75MTurnover
LossP/E Static
-18.70P/B
0.00%Div Yield TTM
-135.05%ROA
17.40052wk High
1.28Volume Ratio
-13.40MNet Profit
8.09MShares
-50.6700EPS TTM
2.19Beta
-3036.44%ROE
3.54452wk Low
8.03%Amplitude
100.00%Gross Margin
102.15MMarket Cap
-0.26Reward/Risk
7.71%Risk Rate
Kazia Therapeutics Ltd News
More news coming soon, stay tuned...
Earnings Forecast
Analyst Rating
Based on
5
analysts
Buy
Current Rating
27.800
Target Price
+131.09%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
496
Total
6
Median
7
Average
Company name
Ratings
Analysts
Kazia Therapeutics Ltd
KZIA
5
Beigene Ltd
ONC
28
argenx SE
ARGX
26
Ionis Pharmaceuticals Inc
IONS
26
IQVIA Holdings Inc
IQV
25
Insmed Inc
INSM
23
1
2
3
...
99
Indicators
Moving Average
Indicators
Value
Direction
MA5
12.474
Buy
MA10
12.997
Sell
MA20
13.106
Sell
MA50
13.069
Sell
MA100
11.654
Buy
MA200
9.762
Buy
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Kazia Therapeutics Ltd Info
Kazia Therapeutics Limited is an oncology-focused drug development company. The Company operates in the pharmaceutical research and development business. The Company’s lead program is paxalisib, an investigational brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway, which is being developed to treat multiple forms of brain cancer. It is also developing EVT801, a small-molecule inhibitor of VEGFR3, which is critical to the development of new blood vessels and lymphatic vessels in a growing tumor, as well as to the metastasis of tumors to distant sites in the body. It designed paxalisib to inhibit PI3K, a critical control mechanism in growth and cell division, which is activated in many forms of cancer. The Company’s drug candidates are designed to treat diseases, such as brain cancer, renal cancer, and liver cancer.
Ticker SymbolKZIA
CompanyKazia Therapeutics Ltd
CEOFriend (John E)
Websitehttps://www.kaziatherapeutics.com/
Shareholders
Related Instruments
-0.53%
+0.27%
-0.92%
-2.51%
+0.32%
-1.45%
-0.64%
-0.82%
-8.79%
+0.52%
+0.68%
-0.95%
-0.71%
+0.44%
-1.08%
+3.29%
0.00%
+1.30%
-0.90%
-2.15%Popular Instruments
52378.000
+109.000 (+0.21%)
28160.900
-37.600 (-0.13%)
7475.100
+30.800 (+0.41%)
14749.000
-90.000 (-0.61%)
62852.000
-742.000 (-1.17%)
6365.400
-1.000 (-0.02%)
85.934
+2.764 (+3.32%)
308.910
-24.520 (-7.35%)
200.750
+5.710 (+2.93%)
4041.430
-61.400 (-1.50%)
FAQs
What is the current price of Kazia Therapeutics Ltd (KZIA)?
The current price of Kazia Therapeutics Ltd (KZIA) is 12.62.
What is the symbol of Kazia Therapeutics Ltd?
The ticker symbol of Kazia Therapeutics Ltd is KZIA.
What is the 52-week high of Kazia Therapeutics Ltd?
The 52-week high of Kazia Therapeutics Ltd is 17.40.
What is the 52-week low of Kazia Therapeutics Ltd?
The 52-week low of Kazia Therapeutics Ltd is 3.54.
What is the market capitalization of Kazia Therapeutics Ltd?
The market capitalization of Kazia Therapeutics Ltd is 102.15M.
Is Kazia Therapeutics Ltd (KZIA) currently rated as Buy, Hold, or Sell?
According to analysts, Kazia Therapeutics Ltd (KZIA) has an overall rating of Buy, with a price target of 27.80.
What is the Earnings Per Share (EPS TTM) of Kazia Therapeutics Ltd (KZIA)?
The Earnings Per Share (EPS TTM) of Kazia Therapeutics Ltd (KZIA) is -12.22.